Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic A/S - Articles of Association27 Aug 2009
Bavarian Nordic in negotiations with the US authorities for the further development of IMVAMUNE®24 Aug 2009
New Review on PROSTVAC(TM) published by key Investigators from NCI1 Jul 2009
PROSTVAC(TM) data presented at the ASCO Meeting demonstrates the potential for significant increases in life expectancy in late-stage prostate cancer30 May 2009
Bavarian Nordic A/S - Report on the Results of the Extraordinary General Meeting, held 18 May 200918 May 2009
The court supports Bavarian Nordic's decision to start patent infringement case against Oxford BioMedica9 May 2009
Bavarian Nordic A/S - Notice convening Extraordinary General Meeting30 Apr 2009
Bavarian Nordic A/S - Interim Report for the period 1 January to 31 March 200927 Apr 2009
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 27 April 200927 Apr 2009
PROSTVAC(TM) data accepted for an oral presentation at the ASCO Annual Meeting16 Apr 2009
Bavarian Nordic A/S - Notice convening ordinary general meeting2 Apr 2009
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such2 Apr 2009
  • Previous
  • 1
  • More pages
  • 56
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 57
  • 58
  • More pages
  • 78
  • Next
  • Filings
    927